Evidence map›Paper›PMID 40095051›Full record

ReviewNaunyn-Schmiedeberg's archives of pharmacology2025

Oxidative phosphorylation and breast cancer progression: insights into PGC-1α's role in mitochondrial function.

Rihab Akasha, Jerlyn Apatan Enrera, Syeda Bushra Fatima, A M Hegazy, Weiam Hussein, Muhammad Nawaz, Maali D Alshammari, Sultan Almuntashiri, Najah Albadari, Mohammed Khaled Bin Break and 1 more

Abstract readReview
PubMed Publisher
In one paragraph

Review in Naunyn-Schmiedeberg's archives of pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Rihab AkashaDepartment of Medical Laboratory Sciences, College of Applied Medical Sciences, University of Hail, 2440, Hail, Saudi Arabia.
Jerlyn Apatan EnreraDepartment of Medical Laboratory Sciences, College of Applied Medical Sciences, University of Hail, 2440, Hail, Saudi Arabia.
Syeda Bushra FatimaDepartment of Clinical Nutrition, College of Applied Medical Sciences, University of Hail, Hail, Kingdom of Saudi Arabia.
A M HegazyDepartment of Medical Laboratory Sciences, College of Applied Medical Sciences, University of Hail, 2440, Hail, Saudi Arabia.
Weiam HusseinDepartment of Pharmaceutical Chemistry, College of Pharmacy, University of Ha'il, Ha'il, Saudi Arabia.
Muhammad NawazDepartment of Nano-Medicine Research, Institute for Research and Medical Consultations, Imam Abdulrahman Bin Faisal University, 31441, Dammam, Saudi Arabia.
Maali D AlshammariDepartment of Pharmaceutical Chemistry, College of Pharmacy, University of Ha'il, Ha'il, Saudi Arabia.
Sultan AlmuntashiriDepartment of Clinical Pharmacy, College of Pharmacy, University of Ha'il, Ha'il, Saudi Arabia.
Najah AlbadariDepartment of Pharmaceutical Chemistry, College of Pharmacy, University of Ha'il, Ha'il, Saudi Arabia.
Mohammed Khaled Bin BreakDepartment of Pharmaceutical Chemistry, College of Pharmacy, University of Ha'il, Ha'il, Saudi Arabia. m.binbreak@uoh.edu.sa.
Rahamat Unissa SyedDepartment of Pharmaceutics, College of Pharmacy, University of Ha'il, 81442, Hail, Saudi Arabia. ru.syed@outlook.com.

Funding

University of Ha'il RG-24 162
6 · The paper itself

Abstract

Breast cancer still ranks high as a leading cause of mortality in women due to its complex relationship with metabolic reprogramming and tumor progression. The peroxisome proliferator-activated receptor gamma coactivator-1α (PGC-1α), a key transcriptional coactivator regulating mitochondrial biogenesis and oxidative phosphorylation (OXPHOS), plays a dual role in breast cancer metabolism. On the one hand, PGC-1α enhances mitochondrial function and energy production, facilitating tumor survival and metastasis, particularly in hypoxic environments. On the other hand, its suppression can limit tumor aggressiveness and energy metabolism. This dual functionality underscores its context-dependent role in cancer progression, where its activation or inhibition varies across tumor subtypes and microenvironmental conditions. The purpose of this review is to provide a comprehensive understanding of PGC-1α's dual roles in breast cancer, elucidating its regulation of mitochondrial function, its contribution to tumor progression, and the therapeutic implications of targeting this key metabolic regulator.

Indexed as

Breast NeoplasmsMitochondriaOxidative PhosphorylationPeroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alphaAnimalsDisease ProgressionEnergy MetabolismFemaleHumansPeroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alphaPPARGC1A protein, humanBreast cancerMetabolic reprogrammingMitochondrial functionOxidative phosphorylationPGC-1αTumor progression

Identifiers

PMID40095051

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.